Fig. 3

2D NMs as drug candidates and gene-therapeutic drugs carriers. A Illustration for GDYO therapy against DNMT3A-mutant AML cell. B Cell viability assay of DNMT3A-mutant AML cell (OCI-AML2 and OCI-AML3) treated with different carbon-based nanomaterials for 24 h. C Apoptotic rates (left) and cell adhesion assay on fibronectin (right) for DNMT3A-mutant AML cell (OCI-AML3) and DNMT3A-wildtype AML cell (HL-60) treated with GO/GDYO for 48 h. D IVIS spectrum images of mice with different treatments. E Kaplan–Meier survival curve of AML mice injected with saline or GDYO. (Reproduced with permission from Ref. [¹⁰⁶], Copyright 2022, Springer Nature) F Schematic illustration of the construction and theranostic mechanism of the siR/IONs@LDH nanoplatform. G Protein expression levels of DHODH in 4T1 cells determined by a western blot assay. H Cell viability of 4T1 cells with different treatments. I Mean tumor volume of resected tumors when 4T1 tumor-bearing mice were sacrificed on day 14. J Photographs of resected tumors when 4T1 tumor-bearing mice were sacrificed on day 14. (Reproduced with permission from Ref. [¹³⁶], Copyright 2023, American Chemical Society)